PRESS RELEASE published on 04/07/2026 at 07:00, 5 months 12 days ago Communiqué de presse: Le lunsekimig de Sanofi a atteint les critères d’évaluation principal et secondaires clés dans les études respiratoires de phase 2 dans l’asthme et la rhinosinusite chronique avec polypose nasale Des études de phase 2 du lunsekimig de Sanofi dans l'asthme et la rhinosinusite chronique confirment son efficacité. Les résultats soutiennent un nouveau traitement respiratoire prometteur Traitement Sanofi Phase 2 Asthme Rhinosinusite
PRESS RELEASE published on 04/07/2026 at 07:00, 5 months 12 days ago Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP Sanofi's lunsekimig meets primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP, showing promising results for managing respiratory diseases Respiratory Diseases Sanofi Asthma Lunsekimig Phase 2 Studies
BRIEF published on 03/28/2026 at 16:05, 5 months 22 days ago L'amlitelimab de Sanofi présente des résultats prometteurs dans les études de phase 3 sur la dermatite atopique Développement Clinique Sanofi Dermatite Atopique Études De Phase 3 Amlitelimab
BRIEF published on 03/28/2026 at 16:05, 5 months 22 days ago Sanofi's Amlitelimab Shows Promising Results in Phase 3 Atopic Dermatitis Studies Clinical Development Sanofi Atopic Dermatitis Phase 3 Studies Amlitelimab
PRESS RELEASE published on 03/28/2026 at 16:00, 5 months 22 days ago Communiqué de presse : AAD : Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute Sanofi présente de nouveaux résultats de phase 3 pour l'amlitelimab dans la dermatite atopique lors d'une session de dernière minute à l'American Academy of Dermatology (AAD) de 2026 Étude Clinique Sanofi Phase 3 Dermatite Atopique Amlitelimab
PRESS RELEASE published on 03/28/2026 at 16:00, 5 months 22 days ago Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Positive results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented at AAD Annual Meeting, showing progressive efficacy with Q12W dosing potential Sanofi Phase 3 Atopic Dermatitis Amlitelimab Q12W
BRIEF published on 03/27/2026 at 13:05, 5 months 23 days ago Sanofi's Sarclisa SC Recommended for EU Approval Sanofi Multiple Myeloma EU Approval Sarclisa SC On-Body Injector
BRIEF published on 03/27/2026 at 13:05, 5 months 23 days ago Sanofi : Approbation UE recommandée pour Sarclisa sous-cutané Sanofi Myélome Multiple Sarclisa CHMP Injecteur Portable
BRIEF published on 03/27/2026 at 13:05, 5 months 23 days ago Sanofi: EU approval recommended for subcutaneous Sarclisa Sanofi Multiple Myeloma Sarclisa CHAMP Portable Injector
BRIEF published on 03/27/2026 at 13:05, 5 months 23 days ago Sarclisa SC de Sanofi recommandé pour une approbation européenne Sanofi Myélome Multiple Approbation De L'UE Sarclisa SC Injecteur Corporel
Published on 09/19/2026 at 00:55, 23 hours 51 minutes ago Gossan Resources Announces Changes to Board and Management
Published on 09/18/2026 at 22:00, 1 day 2 hours ago Silver Tiger Announces Results of Annual and Special Meeting
Published on 09/18/2026 at 20:35, 1 day 4 hours ago Only 11% of Marketers Expect Google Search to Be Their Customers' Main Starting Point in Two Years
Published on 09/18/2026 at 14:30, 1 day 10 hours ago AIAI Holdings to Obtain a Controlling Position in Messier 42 Marketing Agreement
Published on 09/19/2026 at 16:40, 8 hours 5 minutes ago 2026 Cross-Strait (Kunshan) Mid-Autumn Lantern Festival Opens
Published on 09/19/2026 at 13:15, 11 hours 31 minutes ago Eurobattery Minerals AB has received information regarding court judgment and criminal suspicion concerning the CEO
Published on 09/19/2026 at 07:30, 17 hours 16 minutes ago Hong Kong sets out initiatives to secure long-term development of pillar industries
Published on 09/18/2026 at 18:44, 1 day 6 hours ago EQS-Adhoc: Enapter AG announces preliminary, unaudited figures for the first half of 2026 and restructures its US sales operations – one-off expense of EUR 17 million
Published on 09/18/2026 at 18:34, 1 day 6 hours ago Disclosure of transactions in own shares from September 14 to September 18, 2026
Published on 09/18/2026 at 18:34, 1 day 6 hours ago Déclaration hebdomadaire d'opérations effectuées du 14 au 18 septembre 2026
Published on 09/18/2026 at 17:45, 1 day 7 hours ago Communiqué de presse_Carrefour Bond_Septembre 2026